The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...

Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short ...

Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...

After public health labs in California failed to confirm a positive result, a sample was sent to the CDC, which Thursday said ...

HHMI will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for funds to ...

Happy birthday to Taylor Swift! She’s now old enough to run for president of the United States (not saying she SHOULD, just ...

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

Kaadan is an assistant professor and vascular medicine attending in the cardiology division at Rush University Medical Center ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...